Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

Health insurers will not be covering the cost of a new obesity medication coming on to the market in Ireland. Mounjaro, a ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe ...

New poll shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs if they are ...

If Robert F. Kennedy Jr. and the Trump administration want to make America healthy again, they should let Medicare cover ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Dr. Shweta Akhouri is a board-certified family and obesity ... what role these medications may play in this statistic, but I am optimistic that this trend will continue. The new year is a great ...

but they are not broadly supportive of teens who have obesity using the medications, according to a new poll from The Associated Press-NORC Center for Public Affairs Research. When it comes to ...